Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is…
| Price | $30.54 |
|---|---|
| Market cap | $1.07B |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NYSE |
| 52-week range | 3.59-37.48 |
| Beta | 1.16 |
Explore ANRO's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.